MX357678B - Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43). - Google Patents

Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43).

Info

Publication number
MX357678B
MX357678B MX2014005048A MX2014005048A MX357678B MX 357678 B MX357678 B MX 357678B MX 2014005048 A MX2014005048 A MX 2014005048A MX 2014005048 A MX2014005048 A MX 2014005048A MX 357678 B MX357678 B MX 357678B
Authority
MX
Mexico
Prior art keywords
tdp
specific binding
binding molecules
variants
derivatives
Prior art date
Application number
MX2014005048A
Other languages
English (en)
Other versions
MX2014005048A (es
Inventor
H Weinreb Paul
Nitsch Roger
Hock Christoph
Grazia Barenco Montrasio Maria
Montrasio Fabio
Grimm Jan
Baeriswyl Jean-Luc
Coomaraswamy Janaky
Quintero-Monzon Omar
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of MX2014005048A publication Critical patent/MX2014005048A/es
Publication of MX357678B publication Critical patent/MX357678B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • Psychology (AREA)

Abstract

La presente invención se refiere a nuevas moléculas de unión específica a TDP-43 incluyendo polipéptidos tales como anticuerpos humanos, así como fragmentos, derivados y variantes de estos. También se proporcionan métodos relacionados con estas moléculas de unión específica a TDP-43. También se describen ensayos, kits y soportes sólidos relacionados con moléculas de unión específica a TDP-43, incluyendo polipéptidos tales como anticuerpos humanos. La molécula de unión específica a TDP-43, anticuerpo, cadena o cadenas de inmunoglobulina, así como fragmentos de unión, derivados y variantes de estos pueden usarse en composiciones farmacéuticas y de diagnóstico para inmunoterapia y diagnóstico dirigido a TDP-43, respectivamente.
MX2014005048A 2011-10-28 2012-10-26 Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43). MX357678B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553113P 2011-10-28 2011-10-28
PCT/IB2012/002905 WO2013061163A2 (en) 2011-10-28 2012-10-26 Tdp-43 specific binding molecules

Publications (2)

Publication Number Publication Date
MX2014005048A MX2014005048A (es) 2014-11-10
MX357678B true MX357678B (es) 2018-07-19

Family

ID=47720540

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014005048A MX357678B (es) 2011-10-28 2012-10-26 Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43).
MX2018008680A MX2018008680A (es) 2011-10-28 2014-04-25 Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018008680A MX2018008680A (es) 2011-10-28 2014-04-25 Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).

Country Status (18)

Country Link
US (3) US9587014B2 (es)
EP (2) EP2771359B1 (es)
JP (3) JP6240611B2 (es)
KR (2) KR101961508B1 (es)
CN (1) CN104159918B (es)
AU (1) AU2012327211C9 (es)
BR (1) BR112014010161B1 (es)
CA (2) CA3112082A1 (es)
CL (1) CL2014001074A1 (es)
EA (1) EA032003B1 (es)
ES (1) ES2883212T3 (es)
HK (1) HK1201846A1 (es)
IL (2) IL232219B (es)
MX (2) MX357678B (es)
MY (1) MY167795A (es)
SG (1) SG11201401735WA (es)
WO (1) WO2013061163A2 (es)
ZA (1) ZA201403680B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
EP2771359B1 (en) 2011-10-28 2021-05-19 Biogen International Neuroscience GmbH Tdp-43 specific binding molecules
US11401321B2 (en) 2013-06-11 2022-08-02 Paul Scherrer Institut Method for determining mutateable ligand-GPCR binding at single amino acid resolution and pairs of mutated ligand and GPCR
EP3099712A4 (en) * 2014-01-31 2017-11-08 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
CN104497121A (zh) * 2014-08-29 2015-04-08 苏州顺升桥生物科技有限公司 淀粉样蛋白tdp-43及其用途
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
TWI592423B (zh) * 2014-10-03 2017-07-21 中央研究院 可辨識致病性ｔｄｐ－４３之抗體及其用途
US9796778B1 (en) 2014-10-03 2017-10-24 Academia Sinica Antibodies against pathological forms of TDP-43 and uses thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2017111166A1 (ja) * 2015-12-25 2017-06-29 国立大学法人東京農工大学 Ｔｄｐ－４３細胞内存在量関連疾患治療剤
PL3430397T3 (pl) 2016-03-14 2022-04-04 Biogen International Neuroscience Gmbh Oznaczenie fagocytozy zależnej od przeciwciał do wiarygodnych pomiarów wychwytu zagregowanych białek
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
MA47163A (fr) 2016-12-16 2019-11-06 Biogen Ma Inc Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé
US11603406B2 (en) * 2017-03-14 2023-03-14 Five Prime Therapeutics, Inc. Antibodies binding to VISTA at acidic pH
WO2018218352A1 (en) * 2017-05-30 2018-12-06 The University Of British Columbia Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto
MA49947B1 (fr) 2017-08-22 2023-03-31 Biogen Ma Inc Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
EP3724232A4 (en) 2017-12-14 2021-12-15 The University of Ottawa EXOSOME PACKAGING AND TARGETED AUTOPHAGY
WO2019118527A1 (en) * 2017-12-14 2019-06-20 The Johns Hopkins University Novel anti-fungal inhibitors
MX2020006956A (es) * 2018-01-05 2020-11-06 Ac Immune Sa Moleculas de union a tdp-43 mal plegadas.
JP7320282B2 (ja) * 2018-03-16 2023-08-03 国立大学法人滋賀医科大学 異常ｔｄｐ－４３を分解除去する抗体断片
TW202019398A (zh) * 2018-06-28 2020-06-01 張翔毓 用於治療或預防構形疾病之方法及藥物篩選方法
MX2021004772A (es) 2018-10-29 2021-08-16 Biogen Ma Inc Variantes de fc5 humanizado y estabilizado para mejorar el transporte de la barrera hematoencefalica.
WO2020118458A1 (en) * 2018-12-14 2020-06-18 The University Of British Columbia Antibodies to misfolded tdp-43 and methods of use
KR20220012270A (ko) * 2019-05-23 2022-02-03 에이씨 이뮨 에스.에이. 항-tdp-43 결합 분자 및 이의 용도
CN114514240A (zh) * 2019-08-12 2022-05-17 麦考瑞大学 用于治疗的组合物和方法
GB202004863D0 (en) * 2020-04-02 2020-05-20 Univ Oxford Innovation Ltd Method
KR20230025659A (ko) 2020-04-28 2023-02-22 솔라 바이오사이언시즈 엘엘씨 Tdp-43 단백질병증의 치료를 위한 조성물 및 방법
CA3176840A1 (en) * 2020-04-29 2021-11-04 Neil R. Cashman Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use
CN116615452A (zh) 2020-08-14 2023-08-18 Ac免疫有限公司 人源化抗tdp-43结合分子及其用途
US20240003918A1 (en) 2020-11-30 2024-01-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
CN112920264B (zh) * 2021-02-08 2022-07-05 武汉大学 Tdp-43蛋白的o-糖基化突变体及其应用
JP6961278B1 (ja) * 2021-03-10 2021-11-05 国立研究開発法人量子科学技術研究開発機構 生体試料中のｔｄｐ−４３を測定する方法及び装置
EP4351624A1 (en) * 2021-05-27 2024-04-17 Mayo Foundation for Medical Education and Research Methods and materials for treating proteinopathies
CA3231484A1 (en) * 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
WO2023156549A1 (en) 2022-02-16 2023-08-24 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
WO2023194565A1 (en) * 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules
WO2023205579A1 (en) * 2022-04-18 2023-10-26 The Regents Of The University Of California Compositions and methods for disrupting pathological aggregates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688511A (en) * 1991-11-05 1997-11-18 Board Of Regents, The University Of Texas System Cellular protein TDP-43 and regulation of HIV-1 gene expression
EP0934953A2 (en) 1997-12-03 1999-08-11 Boehringer Mannheim Corporation Complex specific antibodies, method of preparation and uses thereof
US8354236B2 (en) * 2006-09-29 2013-01-15 The Trustees Of The University Of Pennsylvania Detection of neurodegenerative disease
CN103408661B (zh) 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
WO2008151055A1 (en) 2007-06-01 2008-12-11 Mayo Foundation For Medical Education And Research Diagnosing neurodegenerative diseases
EP2189526B1 (en) * 2007-07-06 2013-09-04 Tokyo Metropolitan Institute of Medical Science Antibody binding specifically to tdp-43 aggregate
US8889597B2 (en) 2008-02-01 2014-11-18 Washington University Sequences associated with TDP-43 proteinopathies and methods of using the same
MX2011006422A (es) 2008-12-19 2011-09-15 Panima Pharmaceuticals Ag Autoanticuerpos humanos anti-alfa-sinucleina.
CN101634656A (zh) 2009-08-21 2010-01-27 武汉三鹰生物技术有限公司 人tdp-43的单抗包被酶标板的制法及elisa检测试剂盒
EP2771359B1 (en) 2011-10-28 2021-05-19 Biogen International Neuroscience GmbH Tdp-43 specific binding molecules

Also Published As

Publication number Publication date
MY167795A (en) 2018-09-26
EP3964524A1 (en) 2022-03-09
US20170152308A1 (en) 2017-06-01
CA3112082A1 (en) 2013-05-02
JP2017205118A (ja) 2017-11-24
US9587014B2 (en) 2017-03-07
IL270223B (en) 2021-05-31
IL232219A0 (en) 2014-06-30
EA201490825A1 (ru) 2015-01-30
CA2853412C (en) 2021-05-04
JP2015505665A (ja) 2015-02-26
KR20180132977A (ko) 2018-12-12
AU2012327211B2 (en) 2016-03-10
IL232219B (en) 2019-11-28
MX2018008680A (es) 2023-04-18
SG11201401735WA (en) 2014-05-29
CN104159918A (zh) 2014-11-19
NZ624871A (en) 2016-06-24
CL2014001074A1 (es) 2015-01-09
CA2853412A1 (en) 2013-05-02
US10259866B2 (en) 2019-04-16
KR20140100480A (ko) 2014-08-14
MX2014005048A (es) 2014-11-10
JP6240611B2 (ja) 2017-11-29
WO2013061163A3 (en) 2014-03-06
WO2013061163A2 (en) 2013-05-02
ES2883212T3 (es) 2021-12-07
CN104159918B (zh) 2019-09-13
AU2012327211C9 (en) 2016-11-17
BR112014010161B1 (pt) 2022-02-08
EP2771359A2 (en) 2014-09-03
AU2012327211A1 (en) 2013-05-23
JP6652609B2 (ja) 2020-02-26
AU2012327211C1 (en) 2016-09-15
ZA201403680B (en) 2020-05-27
US11091540B2 (en) 2021-08-17
KR102032080B1 (ko) 2019-10-15
HK1201846A1 (en) 2015-09-11
JP2019022500A (ja) 2019-02-14
BR112014010161A2 (pt) 2018-09-25
JP6417451B2 (ja) 2018-11-07
EP2771359B1 (en) 2021-05-19
EA032003B1 (ru) 2019-03-29
US20140255304A1 (en) 2014-09-11
EA201490825A8 (ru) 2016-09-30
US20200017577A1 (en) 2020-01-16
KR101961508B1 (ko) 2019-03-25

Similar Documents

Publication Publication Date Title
PH12021550083A1 (en) Human anti-tau antibodies
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
MX345092B (es) Anticuerpos anti-tau humanos,.
AU2011343161A8 (en) Human anti-SOD1 antibodies
MX2015003150A (es) Anticuerpos específicos de polipeptido amiloide de islote humano (hiapp) y sus usos.
MX357193B (es) Moleculas de union anti-alfa sinucleina.
TN2015000247A1 (en) Bcma antigen binding proteins
TN2014000120A1 (en) Cd27l antigen binding proteins
MX340295B (es) Anticuerpos monoclonales anti-c-met.
IN2014CN03936A (es)
MX360580B (es) Autoanticuerpos humanos anti-alfa-sinucleina.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: WSP GLOBAL INC.

FG Grant or registration